强生肿瘤业务收入10年间翻14倍,现立新目标,计划到2030年将收入提高至500亿美元,是现在的2倍多。其目前主要靠MM产品盈利,实体瘤和血液瘤领域也有布局,但实现目标有难度,需看新产品潜力。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.